Loading...
Loading...
- Koninklijke Philips N.V. PHG reported a third-quarter FY22 comparable sales decline of 5% year-on-year to €4.3 billion.
- Continued supply shortages, inflationary pressures, the COVID situation in China, and the Russia-Ukraine war led to the decline.
- The comparable order intake decreased by 6%.
- Also Read: Philips Names Company Insider Roy Jakobs As New CEO, Succeeding Frans van Houten
- Comparable sales for Diagnosis & Treatment businesses declined by 2%.
- The comparable sales in the Connected Care businesses declined 15% Y/Y due to supply challenges.
- The Personal Health businesses recorded a comparable sales growth of 4% Y/Y from the momentum in North America and Western Europe.
- Philips Respironics has produced 4 million replacement devices and repair kits to date.
- Due to lower sales and supply chain headwinds, the adjusted EBITA margin contracted 750 bps to 4.8%.
- Philips used €180 million in operating cash flow.
- Outlook: The supply challenges, macroeconomic environment, and COVID measures in China led to Philips expecting a mid-single-digit comparable sales decline for Q4, with a high-single-to-double-digit Adjusted EBITA margin range.
- During Q2, PHG disclosed a full-year 2022 outlook of 1%-3% comparable sales growth and ~10% Adjusted EBITA margin, driven by 6%-9% comparable sales growth in the second half of 2022.
- For the 2023-2025 period, Philips expected 4%-6% average annual comparable sales growth and an Adjusted EBITA margin of 14%-15%.
- Philips shared plans to reduce its global workforce by around 4,000 roles immediately.
- Price Action: PHG shares closed lower by 1.51% at $13.07 on Friday.
- Photo Via Wikimedia Commons
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in